Literature DB >> 3770011

Disposition of allylic oxidation pathway metabolites of racemic hexobarbital in the rat.

M Van der Graaff, N P Vermeulen, M H Vinks, D D Breimer.   

Abstract

The pharmacokinetics in blood of the major metabolites of hexobarbital (HB), 3'-hydroxyhexobarbital (OH-HB) and 3'-ketohexobarbital (K-HB) were studied in rats. In addition urinary excretion of OH-HB and K-HB and 1,5-dimethylbarbituric acid (DMBA) was determined. Half-lives of OH-HB and K-HB were slightly longer than that of the parent drug. Urinary recovery of OH-HB, K-HB and DMBA following i.a. administration of OH-HB (75%) was more complete than the recovery following i.a. administration of K-HB (52%). Most probably further metabolism of K-HB takes place. Of K-HB, 41% was excreted renally, and 3.4% of K-HB reverted back to OH-HB. Of OH-HB, about 45% was excreted renally, following p.o. or i.a. administration. Since about 10% of both OH-HB and K-HB was converted to DMBA, it seems that the epoxide-diol pathway as proposed for HB also plays a minor role in the metabolism of OH-HB and K-HB. It is further concluded that measuring allylic pathway oxidation metabolites of HB does not improve the usefulness of HB as a model compound in the assessment of the activity of oxidative drug metabolizing activity.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3770011     DOI: 10.1007/BF03189835

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  11 in total

1.  Dehydrogenation of indanol by rabbit liver 3-hydroxyhexobarbital dehydrogenase.

Authors:  R Takenoshita; S Toki
Journal:  Xenobiotica       Date:  1977-06       Impact factor: 1.908

2.  Rabbit liver 3-hydroxyhexobarbital dehydrogenase. Purification and properties.

Authors:  R Takenoshita; S Toki
Journal:  J Biol Chem       Date:  1974-09-10       Impact factor: 5.157

3.  The metabolic fate of hexobarbital in the rat.

Authors:  R R Holcomb; N Gerber; M T Bush
Journal:  J Pharmacol Exp Ther       Date:  1974-01       Impact factor: 4.030

4.  Disposition of hexobarbitone in healthy man: kinetics of parent drug and metabolites following oral administration.

Authors:  N P Vermeulen; C T Rietveld; D D Breimer
Journal:  Br J Clin Pharmacol       Date:  1983-04       Impact factor: 4.335

5.  The epoxide-diol pathway in the metabolism of hexobarbital in rat and man.

Authors:  N P Vermeulen; B H Bakker; J Schultink; A van der Gen; D D Breimer
Journal:  Xenobiotica       Date:  1979-05       Impact factor: 1.908

6.  Metabolism of drugs. XVI. The metabolic fate of methylhexabital (5-cyclohexenyl-3,5-dimethylbarbituric acid). 6. Studies on the reduction of 3-keto-MHB (5-(3-oxo-1-cyclohexenyl)-3,5-dimethylbarbituric acid) and on pharmacological activity of the biotransformation products of methylhexabital from the urine of rabbits.

Authors:  H YOSHIMURA
Journal:  Chem Pharm Bull (Tokyo)       Date:  1958-02       Impact factor: 1.645

7.  Correlation between the in vivo metabolism of hexobarbital and antipyrine in rats.

Authors:  M van der Graaff; N P Vermeulen; R P Joeres; T Vlietstra; D D Breimer
Journal:  J Pharmacol Exp Ther       Date:  1983-11       Impact factor: 4.030

8.  Pharmacokinetics of simultaneously administered hexobarbital and heptabarbital in rats: an alternative approach to metabolic correlation studies.

Authors:  M van der Graaff; N P Vermeulen; P N Langendijk; D D Breimer
Journal:  J Pharmacol Exp Ther       Date:  1983-06       Impact factor: 4.030

9.  Disposition of hexobarbital enantiomers in the rat.

Authors:  M van der Graaff; N P Vermeulen; R P Joeres; D D Breimer
Journal:  Drug Metab Dispos       Date:  1983 Sep-Oct       Impact factor: 3.922

10.  Disposition of hexobarbital in the rat. Estimation of "first-pass" elimination and influence of ether anesthesia.

Authors:  N P Vermeulen; M Danhof; I Setiawan; D D Breimer
Journal:  J Pharmacol Exp Ther       Date:  1983-07       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.